Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406228 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL872853 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL3383981 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL1532457 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL406229 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL1771437 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL9933295 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21485374 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21485375 | 1.00 | ADORA3 (0.39) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL1868201 | 0.93 | ALDH1A1 (0.37) | ADORA3NR1I2PTGS2PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090555-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | claimed |
| EP-1937365-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| EP-4435080-B1 | A PROCESS OF MAKING A SALTED SPRAY-DRIED PERFUME MICROCAPSULE PARTICLE | PROCTER & GAMBLE (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12371642-B2 | Benefit agent containing delivery particle | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3955900-B1 | POLYMERIC CAPSULES | PROCTER & GAMBLE (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025056470-A1 | AQUEOUS-BASED PERFUME COMPOSITION | JAFER ENTERPRISES R&D SL (ES) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024213455-A1 | USE OF A COMPOSITION, IN PARTICULAR A FRAGRANCING COMPOSITION, COMPRISING DIETHYL SUCCINATE AND A TERTIARY AMINE | JAFER ENTERPRISES R&D SL. (ES) | 2024-10-17 | — | — | WO | disclosed |
| US-20240316523-A1 | PROCESS OF MAKING A SALTED SPRAY-DRIED PERFUME MICROCAPSULE PARTICLE | PROCTER & GAMBLE COMPANY, THE | 2024-09-26 | — | — | US | disclosed |
| EP-2468239-A1 | Encapsulates | Procter & Gamble International Operations SA (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20120152268-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2012-06-21 | — | — | US | disclosed |
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | disclosed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | TAS2R60, TAS2R40, LPO | ADORA3 3656/4885NR1I2 2892/4885PTGS2 2606/4885 |
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | LPO, QDPR, TYR | ADORA3 2556/4885NR1I2 1139/4885PTGS2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.